AUAUniversity

American Urological Association
  • 4.5 (37)
  • EDUCATION
  • UPDATED WEEKLY
AUAUniversity

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

  1. AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025

    1D AGO

    AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025

    AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

    1h 46m
  2. AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them

    MAY 14

    AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them

    AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them CME Available: https://auau.auanet.org/node/43041 At the conclusion of this activity, participants will be able to: 1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer. 2. Risk-stratify patients with non muscle- invasive bladder cancer. 3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin. 4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease. 5. Individualize patient surveillance according to risk stratification. 6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management. ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grants from: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

    2h 1m
  3. AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer

    MAY 7

    AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer

    AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer CME Available: https://auau.auanet.org/node/43069 At the conclusion of this CME activity, participants will be able to: 1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring. 2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease. 3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings. 4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach. 5. Identify patients with radiorecurrent organ-confined prostate cancer. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging Novartis Pharmaceuticals Corporation

    1h 43m
  4. AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team

    APR 30

    AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team

    AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://auau.auanet.org/node/42822 At the conclusion of this CME activity, participants will be able to: 1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer. 2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy. 3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes. 4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing. 5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination. ACKOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Merck & Co., Inc.

    44 min
  5. Live from AUA2025: Advances in ADT Program

    APR 29

    Live from AUA2025: Advances in ADT Program

    Live from AUA2025: Advances in ADT Program CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1 ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Pfizer, Inc. Sumitomo Pharma America, Inc. At the conclusion of this CME activity, participants will be able to: 1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice 2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings. 3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT. 4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes. 5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT. 6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.

    1h 4m
  6. AUA2025: Sexual Medicine Society of North America Meeting

    APR 23

    AUA2025: Sexual Medicine Society of North America Meeting

    AUA2025: Sexual Medicine Society of North America Meeting Cohost: Landon Trost, MD Outline: Segment #1: What is the Sexual Medicine Society of North America and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SMSNA meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SMSNA meeting at AUA2025?

    17 min
  7. AUA2025: Society of Urological Robotic Surgeons Meeting

    APR 21

    AUA2025: Society of Urological Robotic Surgeons Meeting

    AUA2025: Society of Urological Robotic Surgeons Meeting Cohost: Michael D. Stifelman, MD Outline: Segment #1: What is the Society of Urological Robotic Surgeons and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the SURS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SURS meeting at AUA2025?

    21 min
  8. AUA2025: Focal Therapy Society Meeting

    APR 16

    AUA2025: Focal Therapy Society Meeting

    AUA2025: Focal Therapy Society Meeting Cohost: Rafael Sanchez-Salas, MD Outline: Segment #1: What is the Focal Therapy Society and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting? Segment #3: What are the main clinical areas being highlighted at the FTS meeting at AUA2025? Segment #4: What is new or exciting on the horizon in your sub-specialty? Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the FTS meeting at AUA2025?

    21 min
See All (346)

4.5
out of 5
37 Ratings

About

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

Information

  • Creator
    American Urological Association
  • Years Active
    2016 - 2025
  • Episodes
    346
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    AUAUniversity

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada